There’s a quiet kind of strength that doesn’t get applause. It’s not loud or dramatic. It’s the strength it takes to keep going when your body feels like it’s quitting on you. The kind that gets up anyway, that smiles through fatigue, that finds peace in small moments others might…
Read more
Health Canada has approved Roche’s PiaSky (crovalimab) for treating paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents, ages 13 and older, who weigh at least 40 kg (88 pounds). The treatment is the first one approved in Canada that’s administered via monthly injections under the skin, or subcutaneously,…
Paroxysmal nocturnal hemoglobinuria (PNH) is more than just a tongue twister; it’s a rare, chronic blood disorder that alters every aspect of life. When I was diagnosed with it in 2017, I quickly realized I wouldn’t just be on a physical journey, but also an emotional and informational…
One year of treatment with Fabhalta (iptacopan) boosts hemoglobin levels, eliminates the need for blood transfusions, and eases fatigue in most adults with paroxysmal nocturnal hemoglobinuria (PNH). That’s according to final data from two global Phase 3 clinical trials: APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530), which evaluated…
Get regular updates delivered to your inbox.
